Despite major advances in mechanical and pharmacological reperfusion strategies to
improve acute myocardial infarction (MI) injury, substantial mortality, morbidity, and …

Vascular complications contribute significantly to morbidity and mortality of diabetes mellitus.
The primary cause of vascular complications in diabetes mellitus is hyperglycaemia …

We compared the effects of linagliptin (Lina, a DPP4 inhibitor) and GLP-1 receptor activation
by exenatide followed by exendin-4 in an infusion pump (EX) on infarct size (IS), post …

Metabolic diseases and diabetes represent an increasing global challenge for human health
care. As associated with a strongly elevated risk of developing atherosclerosis, kidney …

Abstract Dipeptidyl peptidase-4 (DPP-4), glycyl-prolyl-naphthylamidase, is a serine protease
that catalyzes the hydrolysis of various proline-containing polypeptides. It is involved in the …

Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are approved drugs
for the treatment of hyperglycemia in patients with type 2 diabetes. These effects are mainly …

Drugs that inhibit dipeptidyl peptidase-4 (DPP-4) are conventionally regarded as incretin-
based agents that signal through the glucagon-like peptide-1 (GLP-1) receptor. However …

The reno-protective effects of antidiabetic dipeptidyl peptidase (DPP)-4 inhibitors have been
studied regarding their antioxidant and anti-inflammatory properties. However, the potential …

Vascular aging is characterized by alterations in the constitutive properties and biological
functions of the blood vessel wall. Endothelial cells (ECs) and vascular smooth muscle cells …

Diabetes-associated cardiovascular complications are the leading cause of death for
diabetic patients. Dipeptidyl peptidase 4 (DPP-4) inhibitor agents, known as gliptins, are a …